High Prevalence of Factor V Leiden in Healthy Jordanian Arabs

A. Awidi; M. Shannak; A. Bseiso; M. A. M. Kailani; M. A. Kailani; N. Omar; B. Anshasi; N. Sakarneh

doi:10.1055/s-0037-1614528

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 81(04): 582-584
DOI: 10.1055/s-0037-1614528

Rapid Communication

Schattauer GmbH

High Prevalence of Factor V Leiden in Healthy Jordanian Arabs

Authors

A. Awidi

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan
M. Shannak

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan
A. Bseiso

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan
M. A. M. Kailani

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan
M. A. Kailani

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan
N. Omar

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan
B. Anshasi

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan
N. Sakarneh

¹From the Department of Medicine, Faculty of Medicine, Jordan University, Amman, Jordan

Abstract

Summary

The prevalence of APC resistance in healthy Jordanian Arabs was studied. Between October 1996 through September 1997 a total of 400 healthy subjects were studied. There were 212 males and 188 females. APC resistance was studied by functional and DNA methods. There were a total of 52 subjects (13%) who were APC resistant by the functional test. There were 49 subjects (12.25%) who had FV Q⁵⁰⁶ by DNA test. Of these there were 42 heterozygous and 7 homozygous (allele frequency 0.07). None of the subjects had clinical thrombosis. It is concluded that the prevalence of APC resistance due to FV Q⁵⁰⁶ is high in Jordanian Arabs.

Full Text

References

References
1 Dahlbäck B. Inherited thrombophilia: Resistance to protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
2 Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to GLn mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
3 Bertina RM, Keoleman BPC, Koster T, Rosendaal FR, Dirven RH, de Ronde H, vander Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
4 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. E Engl J Med 1994; 330: 517-21.
5 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
6 Rees DC. The population genetics of factor V Leiden (Arg 506 Gln). Br J Haematol 1996; 95: 579-86.
7 Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. Can Med Assoc J 1996; 153: 285-9.
8 Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997; 277: 1305-7.
9 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
10 Takamiya O, Ishida F, Kodaira H, Kifano K. APC-resistance and MnLI genotype (Gln 506) of coagulation factor V are rare in Japanese population (Letter). Thromb Haemost 1995; 74: 996
11 Ozbeck U, Tangun Y. Frequency of factor V Leiden (Arg 506 Gln) in Turkey (Letter). Br J Haematol 1997; 97: 504-5.
12 Dzimiri N, Meyer B. World distribution of factor V Leiden. (Letter). Lancet 1996; 347: 481-2.
13 Hammoud DF, Eldibanny MM, Nowak JA. Prevalence of the factor V leiden mutation in the egyptian population. (Abstract). Blood 1996; 88 (10) (Suppl. 01) (Suppl) 73b.
14 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78 (Suppl. 01) 297-301.
15 Awidi A. Congenital hemorrhagic disorders in Jordan. Thromb Haemost 1984; 51: 331-3.
16 Awidi AS, Abu-Khalaf M, Herzallah U, Abu-Rajab A, Shannak MM, Abu-Obeid T, Al-Taher I, Anshasi B. Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. Am J Hematol 1993; 44: 95-100.
17 Kawasaki ES. Sample preparation from blood, cells and other fluids in: PCR protocols, A guide to methods and applications. Innis MA, Gelfand DH, Shinsky JJ, While TJ. eds. San Diego, Academic Press Inc 1990; 146
18 Bowen DJ, Bowley D, John M, Collins PW. Factor V Leiden (G 1691A), the prothrombin 3’ – untranslated region variant (G 20210 A) and thermolabile methylene tetrahydrofolate reductase (C 677 T): A single genetic test genotypes all three Loci-determination of frequencies in the S. Wales population of U.K. Thromb Haemost 1998; 79: 949-54.
19 Ehrenforth S, Zwinge B, Scharrer I. High prevalence of factor V R 506 Q mutation in German thrombophilic and normal population. Thromb Haemost 1998; 79: 684-5.
20 Vanegas OC, Giusti B, Fernandez MR, Abbate R, Pepe G. Frequency of factor V (FV) Leiden and C 677 T methylene-tetrahydrofolate reductase (MTHFR) mutations in Colombians. Thromb Haemost 1998; 79: 883-4.
21 Castoldi E, Lunghi B, Mingozzi F, Ioannou P, Marchetti G, Bernardi F. New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V Leiden mutation in mediterranean populations and indians. Thromb Haemost 1997; 78: 1037-41.
22 Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, Attanasio M, Prisco D, Gensini GF, Abbate R. Prevalence of factor V Leiden mutation in non-european populations. Thromb Haemost 1997; 77: 329-31.
23 Chaida C, Gialeraki A, Tsoukala A, Maudalaki A. FVQ⁵⁰⁶ in patients with thrombosis in Greece. (Abstract). Thromb Haemost 1997; 77 (06) (Suppl) 224.
24 Lindqvist PG, Svensson PJ, Dahlbäck B, Marsal K. Factor V Q⁵⁰⁶ mutation (activated protein C resistance) associated with reduced intrapartum blood loss – a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
25 Zivelin A, Yakar S, Brenner B, Eldor A, Rosenberg N, Seligsohn U. Haplotype analysis of factor V gene in Arabs and jews suggests that the Arg 506 GLn mutation causing resistance to activated protein C evolved from common ancestor. (Abstract). Br J Haematol 1996; 93 (Suppl. 02) (Suppl) 6-7.
26 Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common caucasian risk factor for venous thrombosis. Blood 1997; 89 (02) 397-402.